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Abstract 
The synthesis and conformational preferences of a set of new synthetic foldamers that 
combine both the -peptoid backbone and side chains that alternately promote cis- and 
trans-amide bond geometries have been achieved and addressed jointly by experiment and 
molecular modeling. Four sequence patterns were thus designed and referred as cis--trans-, 
trans--cis-, cis--trans-, and trans--cis-. - and NtBu monomers were used to 
enforce cis-amide bond geometries and - and NPh monomers to promote trans-amides. 
NOESY and molecular modeling reveal that the trans--cis- and cis--trans- tetramers 
show similar pattern of intramolecular weak interactions. The same holds for the cis--trans-
 and trans--cis- tetramers but the interactions are different in nature than those identified 
in the trans--cis- based oligomers. Interestingly, the trans--cis- peptoid architecture 
allows establishing a larger amount of structure-stabilizing intramolecular interactions. 
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Introduction 
In the past two decades, there has been considerable interest in the construction of synthetic 
oligomers that are capable of adopting a three-dimensional conformational preference, with 
the ultimate aim of establishing a close relationship between conformation, properties and 
functions.1 The term foldamer was proposed by Gellman to designate “polymers with a strong 
tendency to adopt a specific compact conformation”2 and Moore added the notion of 
structures being “stabilized by a collection of non-covalent interactions between nonadjacent 
monomer units”.3 In this context a huge number of bioinspired4 and abiotic foldamers5 whose 
skeleton do not resemble those of biopolymers have been constructed and studied. The 
chemical linkage between the monomers can also be varied expanding backbone chemical 
diversity and playing a major role on the whole conformation. Native amide bonds are by far 
the most widely used linkages in foldamer chemistry, not only for its ease of formation, but 
also for conformational considerations. The amide plane constrains locally the accessible 
conformational space in addition to its role in intramolecular stabilizing hydrogen bonding. 
Secondary amides of peptide strands or foldamer structures preferentially exist in solution in 
the trans form, which is energetically most favorable. In peptides, the cis amide conformation 
is mainly observed in proline-rich peptides and N-methylated peptides, notably cyclic 
peptides. There is a special class of artificial oligoamides, namely peptoids where the amides 
can populate both the cis and trans conformations. Peptoids are glycine oligoamides with 
pendant side chains attached on the amide nitrogen atoms.6 Peptoids are thus characterized by 
tertiary amide bonds (N,N-disubstituted amides) which are prone to cis-trans amide 
isomerism.7 We are now at a point where it is possible to control the conformation of every 
peptoid amide bonds within a sequence. This is a formidable opportunity to expand structural 
diversity of peptoid backbones and foldamers. Oligoamides with an alternating cis-trans 
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amide sequences are very scarce. The alternating cis-trans conformation has been observed 
for oligoprolines with L/D alternating configurations.8 The 4-aminopyroglutamic acids (aPy) 
have been used as dipeptide mimics with an internal amide linkage locked in the cis 
conformation.9 The X–ray structure of a trimer of the aPy building block showed a unique, 
alternating cis-trans sequence of amide bonds. In the peptoid field, the Blackwell group has 
taken advantage of the strong rotameric preference induced by aryl and -chiral aromatic 
naphthylethyl (1npe) side chains to construct peptoid oligomers with a succession of cis and 
trans main-chain amides. A stable ribbon-like structure was thus revealed by NMR and X–ray 
crystal analysis.10 A new and unique peptoid secondary structure referred as “-helix” was 
also demonstrated by both alternation of cis- and trans-promoting side chains and alternation 
of side chain configuration.11 The X–ray structure of a number of constrained cyclic peptoids 
also revealed repetition of the cis-trans sequence pattern.12 Our group has recently described a 
new peptoid backbone comprising of both - and -peptoid monomers in alternation.13 
Herein, we explore the possibility of alternating both  and  monomers and cis and trans 
amide main chains within the sequences. - and -NtBu monomers were used for enforcing 
cis-amides and - and -NPh monomers for trans-amides.14 Hence, we designed four novel 
peptoid architectures comprising the  backbone and alternating cis-trans amides. In this 
study, we present their synthesis, full NMR analysis and computational study at the tetramer 
length (compounds 6, 12, 19 and 27 in Figure 1). 
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Figure 1. Peptoid architectures based on the alternating -peptoid backbone and alternation 
of cis and trans amide bond geometries. CHANGE LABELS IN CDX 
 
Results 
Peptoids oligomers are basically more flexible than many other oligoamide-based foldamers 
due to their inability to establish intramolecular backbone hydrogen-bond networks, achirality 
of their backbone and equilibria between the cis and trans tertiary amide conformations. The 
latter should however be considered as an advantage since it allows exploring a greater 
conformational space. A great body of work enabled identifying requirements for peptoid 
chain folding into discrete structures. Hence, -peptoids composed of NC-chiral aromatic 
side chains or bulky side chains fold preferentially into the PolyProline-type I helical structure 
(PPI) with all the amides in cis,15 whereas N-aryl peptoids resemble the Polyproline-type II 
helix, with the amides in trans.16 It should be noted, however, that with the exception of 
cyclic peptoids, the number of high-resolution structures is still scarce. This is for a large part 
attributable to an imperfect control of the amide geometry, giving rise to a substantial 
conformational heterogeneity. A small number of side chains have been recently designed to 
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impose tighter control over the amide geometry through steric and stereoelectronic effects. 
One of the most effective way to induce the cis conformation is the -chiral aromatic (S)-1-
(1-naphthyl)ethyl (s1npe) group, as shown in peptoid model systems and homooligomers that 
contain exclusively cis amide bonds above the tetramer length.15d Other such side chains are 
the triazolium17 and tert-butyl (tBu)18 which strongly favor cis peptoid amides predominantly 
based on electronic and steric effects, respectively. The tert-butyl group even allows a 
complete locking of peptoid amides in cis, independently of the solvent. Despite the achirality 
of tBu groups, it was even shown that weak non-covalent interactions, including tBu…tBu 
dispersive interactions help promote helix folding.18 The trans peptoid amide conformation, 
on the other hand, is mainly favored by the use N-aryl side chains, with cis/trans ratios ≥ 95:5. 
We now report on new peptoid platforms design that combines the -backbone and cis and 
trans amides in alternation. Four sequence patterns were thus devised from the above-
mentioned structural elements: cis--trans-, trans--cis-, cis--trans-, and trans--cis-. 
The corresponding compounds were synthesized at the tetramer length (compounds 6, 12, 19, 
and 27) with tBu side chains to impose cis peptoid amide geometries and phenyl (Ph) side 
chain for the trans conformation. 
 
Synthesis of tetramer 6 (Ac-NtBu-NPh-NtBu-NPh-OEt). -Peptoids are most often 
synthesized in high yield and good purity by the solid-phase submonomer protocol described 
by Zuckermann et al.19 A solid-phase submonomer approach has been adapted to the 
synthesis of -peptoids20 but efficacy of the two-steps iterative process (acylation with 
acryloyl chloride followed by aza-Michael addition of primary amines) has been shown to be 
limited by the second step of the iteration. As our goal was to make short oligomers (4-mers), 
but also and more importantly due to the deactivated character of aryl amines and the 
presence of sterically demanding tBu groups within the sequences, we decided to synthesize 
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peptoid oligomers in solution. The initial general synthetic strategy involving the 
submonomer synthesis of N-to-C - and -dimeric building blocks, and their subsequent 
coupling to form tetramers was considered the most straightforward. We also anticipated that 
the development of a fragment-based coupling strategy would be suitable for the synthesis of 
longer oligomers. This strategy was first assessed for the synthesis of tetramer 6 trans--cis-
) (Scheme 1). The synthesis began by treatment of ethyl bromoacetate with 2 equivalents of 
aniline in chloroform to yield the desired peptoid monomer 1 in modest yield. The next 
residue (NtBu -alanine) was constructed by the two-step submonomer approach including 
acylation with acryloyl chloride in the presence of triethylamine in THF (2, 77% yield), and 
aza-Michael addition of tert-butylamine on the formed acrylamide at 60 °C in ethanol (93% 
yield). The formed dimer 3 represents the amine dimeric building block of the forthcoming 
peptide coupling reaction. Therefore, half of the material was kept unchanged and the other 
half was end-capped by an acetyl group before saponification of the ethyl ester to give the 
dimer acid 5, ready for the coupling with 3. Peptide coupling of peptoid segments substituted 
by a sterically hindered tert-butyl group at the N-terminus is very challenging as shown by us 
recently. Taking advantage of our experience, we first examined the use of pentafluorophenyl 
diphenylphosphinate (FDPP) and pentafluorophenyl trifluoroacetate, two reagents which 
allow activation of the acid partner as a pentafluorophenyl ester. Among all the peptide 
coupling techniques tested, only these reagents have allowed us to synthesize NtBu -
peptoids with up to 15 residues.18 Surprisingly, these reagents failed to provide tetramer 6. We 
then tested for the first time the Mukaiyama reagent (2-chloro-1-methylpyridinium iodide: 
CMPI) in the presence of triethylamine, yielding the expected tetramer 6 in 53% yield after 
several optimization reactions. 
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Scheme 1. Synthesis of tetramer 6 
 
 
Synthesis of tetramer 12 (Ac-NtBu-NPh-NtBu-NPh-OEt). The same general 
synthetic approach was applied to the synthesis of tetramer 12 (trans--cis-) (Scheme 2), via 
the submonomer synthesis of a dimer (9), of which a part was converted into the acid partner 
(11) and a final coupling using the Mukaiyama reagent to give tetramer 12. The difference 
between compounds 6 and 12 is the inversion between the - and -residues. Thus, the 
synthesis of 12 started with the preparation of the NPh monomer 7 by addition of aniline 
onto ethyl acrylate in protic solvents at 100 °C following a described procedure.21 Elongation 
consisted in a bromoacetylation reaction and displacement of the bromine with tert-
butylamine to give dimer 9. 
 
Scheme 2. Synthesis of tetramer 12 
 
 
Synthesis of tetramer 19 (Ac-NPh-NtBu-NPh-NtBu-OEt). Afterward we synthesized 
tetramer 19 using the same general strategy. This involved the synthesis of dimer NPh-
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NtBu-OEt following the same route as for the synthesis of compound 3 but switching the 
amines in the sequence (Scheme 3). The submonomer compound 14 was thus prepared and 
treated under the same conditions as for the synthesis of 7 (PhNH2, TFE, H2O, 100°C). 
Unfortunately, these conditions failed to give the expected dimer NPh-NtBu-OEt. 
 
Scheme 3. Attempted synthesis of dimer NPh-NtBu-OEt 
 
 
Tetramer 19 was finally successfully synthesized by a monomer approach in the N-to-C 
direction as shown in Scheme 4. Monomer 7 was first N-capped by an acetyl group followed 
by hydrolysis of the ester to give the acid partner 16. Coupling of 16 with the amine 13 using 
the Mukaiyama reagent afforded dimer 17 in 87% yield. Saponification of 17 (77 % yield) 
and subsequent coupling of the formed acid with 7, still with the CMPI reagent but in the 
presence of DMAP22 afforded trimer 18 (52 % isolated yield), which in turn was hydrolyzed 
to the corresponding acid and converted by Mukaiyama peptide coupling into the expected 
tetramer 19. 
 
 
 
 
 
 
 9
Scheme 4. Synthesis of tetramer 19 
 
 
Synthesis of tetramer 27 (Ac-NPh-NtBu-NPh-NtBu-OEt). For the synthesis of 
tetramer 27, the initial [2+2] fragment based coupling strategy was also considered, which 
implied first the submonomer synthesis of dimer amine 22 as shown in Scheme 5. Compound 
22 was then converted to the corresponding acid in two steps, consisting in the capping of the 
N-terminal as an acetamide and hydrolysis of the ester function (not shown, see SI for details). 
The formed acid dimer was then reacted with amine 22 under peptide coupling conditions, 
with the aim of obtaining the expected tetramer 27. Three attempts were carried out with the 
Mukaiyama reagent, changing the additive base (Et3N, Et3N/DMAP and DBU). None of them 
allowed us obtaining tetramer 27. To address this issue, synthesis of 27 was continued from 
amine 22 using only submonomer protocols. The synthesis of trimer 24 required acylation of 
22 with acryloyl chloride (97% yield) followed by aza-Michael addition of tBuNH2 in 89% 
yield. From 24, a last submonomer cycle (bromoacetylation in 34% yield and bromine 
displacement with aniline in 63% yield) afforded tetramer 26, which was subsequently 
acetylated to give the expected compound 27. 
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Scheme 5. Synthesis of tetramer 27 
 
 
NMR spectroscopic studies. The four synthesized tetramers 6, 12, 19, and 27 were analysed 
by a combination 2D NMR experiments (1H,1H-COSY, 1H,13C-HMQC, and HMBC) that 
allowed full assignment of the proton and carbon NMR spectra. Of note is the observation of 
a single set of resonances for every compound as shown by the 1H-13C HSQC spectra in 
Figure 2. This is indicative of a full control of the amide bonds geometry by the side chains. 
2D-NOESY spectra were acquired to verify geometry of the amides, which, as expected were 
found cis for NtBu monomers and trans for N-aryl monomers (ESI S30). 
 
A 
 
B 
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Figure 2. 1H-13C HSQC spectra of tetramer 6, 12, 19, and 27 (B). The principle of atom 
labeling is shown in (A). 
 
X–ray Crystallography of dimer 17. Single crystals of dimer 17 suitable for X–ray 
diffraction were grown from slow evaporation of a Et2O solution (Figure 3, Table 1). Dihedral 
angles of the NtBu -monomer at the C-terminus match up well with those characterizing 
peptoid monomers in Polyproline type-I helical secondary structure. Analysis of the -NPh 
monomer revealed an extended backbone conformation (1 = -172.8, Table 1) as previously 
observed in the solid-state structure of -peptoid model compounds.23 
The crystal structure was analysed for potential non-covalent interactions (Figure 3). The 
backbone carbonyl groups being oriented roughly perpendicular to each other, implications of 
n → *C=O interactions were considered. One potential n → *C=O interaction was detected 
between the carbonyl oxygen atom of the ester and the carbonyl amide of the precedent 
residue. The carbonyl oxygen atom to carbonyl carbon distance is 3.2 Å, as for an ideal 
polyproline II helix24 and the Oi+1…C’i=O angle is 128°, which is only slightly outside of the 
109 ± 10° window for an optimal orbital overlap. Such C=Oi+1…C’i=O interactions have been 
observed in a -peptoid monomer23 and in an N-aryl/Ns1npe tetramer.10 The directionality of 
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the interaction is however opposite to that which is prevalent in prolyl peptide models (C=Oi-
1…C’i=O)25 or revealed in previous X–ray crystallographic studies of peptoids.16b,26 
 
Table 1. Dihedral angles in dimer 17 
 
1 (trans) 1 1 1 2 (cis) 2 2 
+175.80 -75.6 -172.8 -171.1 +4.9 +81.9 +166.8 
 
 
Figure 3. Solid-state structure of dimer 17 (Ac-NPh-NtBu-OEt) determined by X–ray 
crystallography. (A) single molecule. (B) Packing of 17 within unit cell.  
 
Molecular Dynamics simulations. In order to investigate the folding of oligomers 6, 12, 19 
and 27, their dynamical behavior has been probed by classical molecular dynamics 
simulations. For the 4 types of cis-trans peptoid tetramers (6, 12, 19, and 27), 50 nanoseconds 
simulations were performed. During these simulations, and as noticed in our previous study,18 
no change of peptoid ω dihedral angle was observed. As expected, the tBu and Ph side chains 
N
O
N
O
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2
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O
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induce cis and trans peptoid amide bond geometries, respectively.16a,18 As the folding of 
peptoids is essentially related to the backbone dihedral angles, the probability distribution of 
these angles has been analyzed for each trajectory and plotted in 1D and in 2D Ramachandran 
maps as indicated in Figures S1 to S4. In this study, all initial structures display positive 
values of φ by construction. The mirror image that would display all negative values of φ 
would behave similarly and has not been considered.  
From Table 2 that gather the different angles combinations, it appears that tetramers 12 and 
19 display similar conformational features. The same conclusion can be drawn for tetramers 
27 and 6. As a consequence, regarding the Ramachadran maps provided in ESI and the 
associated remarkable angles summarized in Table 2, general conformational trends can be 
highlighted. It appears that the nature of the side chain (ie tBu vs Ph) influences the value of 
the  angle. The tBu group, that induces a cis amide conformation, also constraints the φ 
angle value that remains unchanged during the simulation time as previously shown by us for 
NtBu oligopeptoids.18 In contrast, the phenyl group, that induces a trans amide 
conformation, also allows more flexibility and fluxionality of the residue with a larger range 
of accessible φ angle values. In addition, a second constraint is imposed by the or nature 
of the peptoid residue. This parameter specifically influences the value of the  angle. As 
expected,  peptoid residues are less flexible and induce a narrower range of  angle values 
than residues. 
Considering all these features, and in accordance with Ramachandran maps, each of the four 
residue involves in the tetramers under study has different conformational behaviors. 
Tetramers 12 and 19 that contain αNtBu residue are characterized by a (ψ,φ) couple of angles 
that remains equal to (+170, +90). In the case of tetramers 6 and 27 that comprise βNtBu 
moiety, this combination of angles takes predominantly the same values (180, +90). However, 
for 6 and 27, two other regions of the Ramachandran plots start to be populated. These 
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regions that spreads toward the value +90 and -90 degrees correspond to the modification of ψ 
angle distribution allowed by the character of the residue. If tetramers 6 and 27 that include 
a αNPh residue are now considered, the main population of the (ψ,φ) couple of angles is at 
(180, +90), as for αNtBu residue, but two additional regions are also populated. One 
corresponds to (180, -90) and is the symmetric of the previous mainly populated area, while 
the second is characterized by a new set of angles (+70, -160) with its symmetric counterpart 
(-70, 160) that is slightly populated for the final fourth residue of tetramer 6. Finally, the more 
“flexible” residue appears to be βNPh that is included in tetramers 12 and 19. For this residue, 
the associated Ramachandran plots exhibit a larger number of populated regions. However, 
depending on the location of this residue within the tetramer, these regions are not equally 
populated. Whilst residue 4 of tetramer 12 almost populates equally the (ψ,φ) regions (180, 
±90), (+90, ±90), (-90, ±90) for symmetric reasons, these population are less pronounced for 
the other βNPh residue locations. For residue 1 in tetramer 19, this population is less 
homogeneous, but 6 regions are still distinguishable in the (ψ,φ) Ramachadran maps. This 
large amount of conformations that are explored by these two residues can be explained by 
the fact that there are terminus residues in the foldamer. In the case of “internal” βNPh 
residue, the population of these regions is more heterogeneous. Residue 3 of 19 clearly shows 
a preference for the (+100,+90) region, even if (-170, ±90) and (-90, -90) regions remain 
slightly populated. The scenario is completely different for residue 2 of tetramer 12. In this 
case, the only region of the (ψ,φ) Ramachadran plot that is populated correspond only to 
(+90,-100). This can be correlated to the value of the  angle that characterizes β peptoid units 
and that has not yet been taken into account. Indeed, for all βNtBu residues, the  angle is 
equal to 180°. For βNPh moiety, this angle is also mostly equal to 180°, except for residue 2 
in tetramer 12 for which this angle take the value of +60°. The (ψ, φ, θ) combination of (+90, 
-100, +60) seems to be also slightly populated for some other βNPh moiety but in a lesser 
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extent. Longer simulation or Replica exchange molecular dynamics would be necessary to be 
performed in order to improve our ergodicity and to improve the population of each region 
that have been highlighted. However 150ns of simulation for such tetramers already allows to 
highlight conformational trends that matches experimental spectroscopic analysis as discussed 
below. In addition, it is worth to note that concerning peptoid 19, simulated structural 
parameters are in agreement with the experimental values determined by X–ray 
crystallography (see Table 2). 
 
 
Table 2. Conformational trends of tetramers 6, 12, 19 and 27 given by averaged simulated 
and experimentally determined dihedral angles. Dihedral angles definition:  [C(i-1); C(i-1); 
N; Cor C], (-monomer) [C(i-1); N; C; C], (-monomer) [C(i-1); N; C; C] (-monomer) [N; C; 
C; N(i+1)], (-monomer) [C; C; C; N(i+1)]. Values in bold indicates preferential 
conformation(s). 
 
Ac-NtBu-NPh-NtBu-NPh-OEt (12) 
residue id.     
αNtBu (1) -10 +90 ±10 +170 ±20 - 
αNtBu (3) -10 +90 ±10 +170 ±20 - 
βNPh (2) 180 
100 10 
+85 10 
+90 10 
+90 10 
+60 10 
+60 10 
βNPh (4) 180 
+90 10 
-90 10 
 90 10 
180 10 
180 10 
 90 10 
180 10 
180 10 
180 10 
 
 16
 
Ac-NPh-NtBu-NPh-NtBu-OEt (19) 
residue id.     
αNtBu (2) -10 +90 ±10 +170 ±20 - 
αNtBu (4) -10 +90 ±10 +170 ±20 - 
17 (X–ray) +5 +82 +167  
βNPh (1) 180 
90 10 
90 10 
-170  20 
+100 20 
180 10 
180 10 
βNPh (3) 180 
+90 10 
90 10 
-90 10 
+100  20 
-170 20 
+100 20 
-170 10 
-170 10 
- 10 
17 (X–ray) +176 -76 -171 -172 
 
Ac-NPh-NtBu-NPh-NtBu-OEt (27) 
residue id.     
αNPh (1) 180 
90 ±20 
-160 ±20 
180 ±20 
+70 ±20 
- 
αNPh (3) 180 
90 ±20 
-160 ±20 
+160 ±20 
180 ±20 
+70 ±20 
-70 ±20 
- 
βNtBu (2) +10 
+90 ±10 
+90 ±10 
+90 ±10 
180 ±20 
+90 ±20 
-90 ±20 
180 ±10 
180 ±10 
180 ±20 
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βNtBu (4) +10 
+90 ±10 
+90 ±10 
+90 ±10 
180 ±20 
+90 ±20 
-90 ±20 
180 ±10 
180 ±20 
180 ±20 
 
Ac-NtBu-NPh-NtBu-NPh-OEt (6) 
residue id.     
αNPh (2) 180 
90 ±20 
-160 ±20 
180 ±20 
+70 ±20 
- 
αNPh (4) 180 
90 ±20 
-160 ±20 
+160 ±20 
180 ±20 
+70 ±20 
-70 ±20 
- 
βNtBu (1) +10 
+90 ±10 
+90 ±10 
+90 ±10 
180 ±20 
+90 ±20 
-90 ±20 
180 ±20 
+170 ±20 
-170 ±20 
βNtBu (3) +10 
+90 ±10 
+90 ±10 
+90 ±10 
180 ±20 
+90 ±20 
-90 ±20 
180 ±20 
+170 ±20 
-170 ±20 
 
 
Quantum Chemical Calculations.  
Energetics and conformations. The energetics associated to the φ angle rotation of αNPh and 
βNPh residues has been evaluated in tetramers 6 and 12, respectively, by means of a relaxed 
energy potential scan computed at the HF/Ahlrichs-VDZ level for optimizations and refined 
at the M06-2X/6-311G(d,p) level for energy evaluations. See the Experimental section for 
details. In both cases, two minima are clearly identified (Figure S5) and dihedral angles 
corresponding to the most stable conformers match the distribution of the φ angle obtained by 
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molecular dynamics (see Figures S1 and S4). For both the αNPh and βNPh residues, the most 
stable conformers are interconnected by low energy transition states (below 6 kcal mol-1). 
This suggests a similar fluxionality of these two residues regarding the φ torsion angle. 
 
 
Figure 4. 3D representation of the optimized geometry at the DFT level of tetramers 6, 12, 
19, and 27 in which representative key weak (CH…O) dispersive interactions are identified by 
their distances (Å). Intra-residue interactions are displayed in black, inter-residue interactions 
are displayed in red. Residue index are given in orange. For these calculations, C-termini of 
tetramers have been capped by NMe2 (prime tag) amide group in place of the ester function 
used experimentally. 
 
From the optimized geometries at the quantum level (Figure 4) and analysis of conformational 
parameters of each tetramer (Table 2), it appears that two main driving forces are responsible 
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for the conformational features of tetramers 6, 12, 19, and 27. One should mention that some 
interaction types displayed in Figure 4 on structures optimized at the quantum level could 
differ from those integrated along classical molecular dynamic trajectories. Firstly, intra-
residue (Ph-H…O=C) hydrogen bondings seem to govern specific conformational properties. 
In the case of tetramers 6 and 27 for which the phenyl side chains are attached to -peptoid 
monomers, this specific interaction is systematically encountered. This can be related to 
almost identical dihedral angles of the NPh residues for these two tetramers (Table 2). By 
contrast, when the phenyl groups are attached to  peptoid residues, the enhanced local 
flexibility in conjunction with the trans character of the peptoid amide bond cannot insure a 
systematic (Ph-H…O=C) hydrogen bond. This is reflected by a greater fluctuation of the  
torsion angles of Ph residues of tetramers 12 and 19. Secondly, the cis conformation 
imposed by the tBu side chains results in systematic weak (tBu)(i+1)CH …O=C(i) interactions18 
independently of the  or  nature of the NtBu monomers. This induces conserved local 
conformations as reflected by similar dihedral angle for the N-tBu residues of tetramers 12 
and 19 on one hand, and tetramers 6 and 27, on the other (Table 2). 
 
Folding driving forces. In our previous study on αNtBu peptoids oligomers, we have shown 
that weak dispersive interactions play a significant role to the peptoid folding.18 One of these 
contributions is the dispersive backbone (i)CH...O=C(i+1) interaction. This interaction has been 
monitored for all the simulations of each tetramer, the result are plotted in Figure S6. For 
tetramers 12 and 19 the carbonyl oxygen atoms of NPh residues (i+1) interact with the Cα 
methylene protons of the precedent NtBu residue (i), and not the vice versa (label blue, Figure 
5). Interestingly, interactions implying the carbonyl oxygen of NPh residues are also revealed 
in compounds 6 and 27, in this case between the C=O of NPh (i+1) residues and the C 
methylene protons of NtBu (i) residues (Figure 5, label green and Figure S7). 
 20
 
 
Figure 5. Main chain CH...O=C interactions in tetramers 6, 12, 19, and 27. Blue (type I), pink 
(type II), and green (type III) tags refers to α(i)CαH…O=C(i+1), (i)CαH…O=C(i+1), and (i) 
CH…O=C(i+1) interactions types, respectively. The arrows (type IV) denotes (tBu)(i+1)CH 
…O=C(i) interactions. Number labels tag the groups in interactions. 
 
Interestingly, only the C methylene groups of NPh residues (i) show a significant amount of 
dispersive interactions with the CO groups of NtBu residues (i+1) (Figure 5, pink label and 
Figure S7). In summary, for the -residues, the C-methylene groups are involved in 
CH...O=C interactions in case of NPh monomers, whereas the C-methylene are involved in 
case of NtBu monomers. (CH…O) dispersive interactions can also develop between the 
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backbone carbonyl oxygens and peptoid side chains.188 Whereas no significant interaction is 
observed between CO and Ph side chains, the C=O of NPh residues (i) interact with the 
methyl groups of the NtBu side chains (i+1) (Figure S8). No significant difference was found 
for this interaction with respect to the four different peptoid chains studied in this work. 
Aside the interactions that involve the polar backbone carbonyl groups, additional weak 
interactions can develop between side chains. Recently, we have demonstrated that side chain 
tBu…tBu interactions help promote helix folding of -peptoids.188 In the present case, 
alternation of tBu and Ph side chains prevents tBu / tBu contact. However, a significant 
amount of interactions is observed between tBu and Ph side chains (Figure S9). As expected, 
these interactions are prominent between adjacent residues. However, peptoids that include 
αNPh residues show a larger amount of interactions than those containing βNPh residues. For 
tetramer 12, exclusively, an interaction is pinpointed between the tBu and Ph side chains at 
the N- and C-termini, respectively. This proximity is supported by The NOESY spectrum of 
tetramer 12 (ESI, S33) 
Finally, a significant amount of Ph-Ph interactions were observed during the simulations 
(Figures S10 and illustration in S11). Peptoids with αNPh residues show more interactions 
than those that comprise βNPh residues. From Figure S10, two patterns of interaction can be 
highlighted. One traduces a random proximity. The other one traduces a edge-to-face stacking 
between two Ph groups. 
 
NMR spectra simulation. 1H and 13C isotropic chemical shifts have been computed for the 
four tetramers. For that purpose, a set of 500 structures has been extracted from each MD 
trajectory. Chemical shielding were calculated at the DFT B3LYP27/6-31G(d,p)28 GIAO 
level29 for each structure, and averaged in order to produce simulated NMR spectra. 
Computed chemical shifts are relative to the theoretical 1H and 13C chemical shielding 
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computed at the same level of theory.30 The fit between experimental and theoretical NMR 
data has been assessed for the four tetramers by means of a linear interpolation. Table 3 
summarizes the parameters related to these interpolations together with additional RMSD 
calculations.  
 
Table 3. Correlation between computed and experimental NMR chemical shifts of tetramers 
6, 12, 19 and 27. 
Cpd. 27 
Ac-(NPh-
NtBu)2-OEt 
12 
Ac-(NtBu-
NPh)2-OEt 
19 
Ac-(NPh-
NtBu)2-OEt 
6 
Ac-(NtBu-
NPh)2-OEt 
13C 
R2 0.9992 0.9992 0.9993 0.9992 
slope 0.92 0.92 0.92 0.92 
intercepta 5.11 5.03 5.00 5.47 
RMSDa 5.14 5.21 5.10 5.28 
1H 
R2 0.9988 0.9981 0.9978 0.9987 
slope 1.07 1.05 1.06 1.05 
intercepta -0.41 -0.28 -0.30 -0.28 
RMSDa 0.22 0.20 0.22 0.18 
a in ppm. R2, slope and intercept result from a linear interpolation. RMSD: root mean square 
difference. 
 
For each tetramer, an excellent correlation between computed and experimental 1H and 13C 
NMR shifts was obtained as illustrated by correlation coefficient higher than 99.78%. The 
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deviation between computed and ideal slope and y-axis intercept, 1 and 0 respectively, 
traduces approximations that are inherent to our computational strategy e.g. empirical force 
field for the structure, solvation models, quantum chemical approximation for the NMR 
calculations. The quality of these results makes us confident in the relevance of our molecular 
dynamics simulations. This also raises the confidence regarding the analysis of the molecular 
conformations generated by molecular dynamic simulations. 
 
Discussion 
Synthesis. The initial plan to synthesize the four target tetramers was based on convergent 
[2+2]-fragment coupling reactions, with the view that this strategy would be very convenient 
for the preparation of longer oligomers. This strategy was effectively applied for synthesizing 
tetramers 6 and 12 using the Mukaiyama reagent (2-chloro-1-methylpyridinium iodide, 
CMPI) as the coupling reagent. These compounds were isolated with average yields of 50%, 
highlighting the difficulties in coupling terminal NtBu peptoids amines.18 In contrast the 
peptoid fragment coupling strategy was not effective to prepare tetramers 19 and 27. 
Regarding the synthesis of tetramer 27, the coupling of the two dimer blocks Ac-NPh-
NtBu-OH and NPh-NtBu-OEt (22) failed, likely to the deactivated character of the 
terminal aryl amine moiety of dimer 22. The submonomer approach using highly reactive 
halogenoacyl reagents, bromoacetylbromide and acryloyl chloride for - and -monomer 
synthesis, respectively, was then implemented for synthesizing tetramer 27. Turning now to 
the synthesis of tetramer 19, comprising NPh and and NtBu residues: Synthesis of the 
required dimer NPh-NtBu-OEt, for subsequent coupling with a dimer acid partner, was not 
feasible because of the low reactivity of the submonomer acrylamide compound 14 towards 
the aza-Michael addition of aniline. Fortunately tetramer 19 could be synthesized by a 
monomer approach in the N-to-C direction, using the Mukaiyama reagent. Synthesis of 
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tetramers 6, 12, 19, and 27 were thus realized in different ways, involving submonomer, 
monomer, and fragment-coupling strategies or any combination thereof. 
Conformational studies. As the set of structures used to simulate 1H and 13C NMR spectra 
are extracted from the Molecular Dynamic simulations initially performed to explore the 
conformation and the dynamics of the four tetramers, the remarkable fit between experimental 
and computed NMR spectra strongly support both the NMR attribution and the MD 
simulation protocol. It also validates the parameters and topologies developed for the non-
standard NPh, NtBu, NPh and NtBu residues. 
A comparative study of the dihedral angles distribution and intramolecular interactions 
highlights similarities between tetramers 6 Ac-(NtBu-NPh)2-OEt and 27 Ac-(NPh-
NtBu)2-OEt on the one hand, and 12 Ac-(NtBu-NPh)2-OEt and 19 Ac-(NPh-NtBu)2-
OEt on the other hand (Table 2). For compounds 6 and 27, analysis of the probability 
distribution of dihedral angles reveals common trends. For example, the NPh residues 2 and 
3 of tetramers 6 and 27, respectively  which are positioned internally within the sequences  
display a conformation featuring torsion angles around (,) = (+75°, 180°). These values are 
consistent with those measured in the crystal structure of Naryl peptoid dimers but a 
deviation is observed from the computationally predicted values (,) = (+60°, ±150°) for 
Naryl oligomers.16a Regarding now the internal NtBu residues 3 (tetramer 6) and 2 
(tetramer 27), they predominantly populate a conformational state around (,,) = (+90°, 
180°, +175°). Interestingly, these torsion angles are very similar to those measured in the 
crystal structure of a -peptoid helix with the amide bonds in the cisgeometry.31 Similarly, 
the NtBu residues of tetramers 12 and 19 adopt common conformational features with (,) 
torsion angles values at about (+90°, +170°), which are reminiscent of those characterizing 
polyproline type I helices.18 Lastly, similarities between the dihedral angles of the NPh 
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residues of 12 and 19 are also observed, with essentially two set of values, (,,) = (±90, 
+100, +180) and (,,) = (±90, ±170, +180). This latter set of dihedral angles matchs up 
well with those determined from the X–ray crystallographic structure of dimer 17 (Ac-(NPh-
NtBu)2-OEt). With the exception of a  value around (+60) for residue 2 of tetramer 12, the 
 dihedral angles are systematically observed at about 180°, which means that the NtBu and 
NPh residues adopt an extended conformation within the oligomers. Analysis of the 
intramolecular interactions also revealed similar characteristics between pair of compounds 
12/19 and 6/27. As highlighted in Figure 5, tetramers 12 and 19 composed of NtBu and 
NPh monomers display (i, i+1) inter-residue (CH…O) hydrogen bonding involving one 
backbone methylene atom of the NtBu (i) residues and the carbonyl oxygen atom of the 
(i+1) NPh residues (type I interaction, Figure 5). An additional (CH…O) interaction between 
adjacent residues is identified in 12 and 19. This involves the backbone C methylene protons 
of NPh monomers and the C=O of the (i+1) NtBu residues (type II). Finally, a third 
interaction between the oxygen atom of the carbonyl groups of the NPh residues (i) and the 
methyl protons of the tBu side chains of the (i+1) residues was found omnipresent within 12 
and 19 (type IV). Hence, two type I, one type II and two type IV  taking into account the N-
terminus acetyl group  interactions participate to the conformational stabilization of tetramer 
12. In tetramer 19, alternation between the same NtBu and NPh residues is maintained. 
Thereof, one type I, two type II and two type IV interactions are identified. At the tetramer 
stage, differences in relative conformational stability of 12 and 19 can be expected, but these 
differences may vanish for longer oligomer length. 
In tetramers 6 and 27, a 4th type of interaction (CH…O=C) is identified between the NPh 
carbonyl backbone oxygens and the Cmethylene protons of NtBu residues (type III, Figure 
5). As a result, in tetramer 27, one type III and two type IV interactions can develop; in 
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tetramer 6, two type III and two type IV  taking into account the N-terminus acetyl group  
and interactions were pinpointed. The same analysis conducted for tetramers 12 and 19 
regarding the length of the oligopeptoids can be transposed to tetramers 6 and 27. 
Interestingly, the amount and the nature of interactions differ between the oligopeptoids 
comprising NtBu and NPh monomers in alternation, on the one hand (exemplified by 
tetramers 12 and 19), and those based on NPh and NtBu on the other (exemplified by 
tetramers 6 and 27). More backbone inter-residue (CH…O) hydrogen bonding can be 
established in oligomers based on the NtBu-NPh dimer unit than in oligomers based on the 
NPh-NtBu one. By contrast, interactions involving only peptoid side chains (tBu/Ph and 
Ph/Ph H…H contacts) are more numerous for tetramers 6 and 27 (NPh-NtBu-based 
oligomers) than for 12 and 19 (NtBu-NPh-based oligomers). It therefore appears that in 
these systems, the more backbone-backbone interactions are present, the less side chain-side 
chain interactions are found, and vice-versa. 
Finally, for compounds 12 and 19 on the one hand and for 6 and 27 on the other, similar 
conformational characteristics have been highlighted by NOESY and molecular dynamic 
simulations. This suggests that the shift in indexation between analogues 12 and 19, and 6 and 
27, does not affect the folding of the tetramers. However, the short length of the oligomers 
limits the number of accessible weak interactions and thus hampers the folding of the peptoid 
tetramers under study 
 
Conclusion 
In this study, we have achieved the synthesis and assessed the conformational preference of a 
set of new oligopeptoid scaffolds that combine an alternated -backbone with a cis and 
trans alternation of the amide links. With this combinatory, four sequence patterns were 
designed and named cis--trans-, trans--cis-, cis--trans-, and trans--cis-. The strict 
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control of the cis/trans conformation of the peptoid amide bonds was enabled, respectively, 
by the use of  and NtBu and  and NPh monomers. The conformation of the four target 
tetramers was probed by NMR spectroscopy and explored by molecular modeling. Both 
experimental and theoretical analyses reveal that the trans--cis- (12) and cis--trans- (19) 
tetramers, comprising both NtBu and NPh monomers, display similar pattern of weak 
intramolecular interactions. Similarly, the cis--trans- (27) and trans--cis- (6) compounds 
involving NPh and NtBu residues show similar patterns of weak inter-residues interactions, 
which are different in nature from those identified in 12 and 19. Among them, several 
backbone (i)CH…O=C(i+1) dispersive interactions between neighboring residues: (i) NtBu / 
NPh, (ii) CH) NPh / NtBu, (iii) CH) NtBu / NPh; and backbone-side chain 
(i)CH…O=C(i-1) interactions: (i) NtBu / NPh, (ii) NtBu / NPh. 
Finally, more intramolecular interactions can be established in oligomers constructed from the 
NtBu and NPh units than from oligomers based on the NPh and NtBu monomers. By 
contrast with NtBu -oligopeptoids, less intramolecular side chain to side chain interactions 
can be established in these novel peptoid families. This study also stresses the diversity of 
weak interactions that can be established within oligopeptoids bearing both aromatic and 
aliphatic side chains as well as the importance of their collectivity along the sequence to 
ensure folding. Considering our experience in synthesizing peptoids with tBu side chains and 
the electronically deactivated character of NPh amines, solution-phase syntheses were 
conducted in this work. Two tetramers (12 and 19) have been constructed from the NtBu and 
NPh monomers and the two others (6 and 27) from the NPh and NtBu monomers. In 
either case, different synthetic strategies were needed to get the target molecules highlighting 
expected difficulties arising from the tBu and Ph side chains. From this work, it appears that 
only tetramers 6 and 12, prepared from dimers 3 (NtBu-NPh-OEt) and 9 (NtBu-NPh-
OEt), could be synthesized following a convergent fragment-based coupling strategy. These 
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dimer building blocks will serve to construct longer oligomers whose folding will depend on a 
collection of local interactions that have been detected in the short peptoids. We anticipate 
that these new systems could serve as suitable platforms to construct high order 
nanostructures showing various features and applications. 
 
EXPERIMENTAL SECTION 
General Information and Materials. 
THF, CH2Cl2 and MeOH were dried over aluminum oxide via a solvent purification system. 
EtOAc, CH2Cl2, cyclohexane, and MeOH for column chromatography were obtained from 
commercial sources and were used as received. Et3N was dried over KOH. All other solvents 
and chemicals obtained from commercial sources were used as received. Melting points were 
determined on a Stuart Scientific SMP3 microscope apparatus and are uncorrected. IR spectra 
were recorded on a Shimadzu FTIR-8400S spectrometer equipped with a Pike Technologies 
MIRacleTM ATR and ν are expressed in cm-1. NMR spectra were recorded on a 400 MHz 
Bruker Avance III HD spectrometer or a 500 MHz Bruker AC-500 spectrometer. Chemical 
shifts are referenced to the residual solvent peak and J values are given in Hz. The following 
multiplicity abbreviations are used: (s) singlet, (ls) large singlet, (d) doublet, (t) triplet, (q) 
quartet, (m) multiplet, and (br) broad. Where applicable, assignments were based on COSY, 
HMBC, HSQC and 13C-experiments. TLC was performed on Merck TLC aluminum sheets, 
silicagel 60, F254. Progression of reactions was, when applicable, followed by NMR and/or 
TLC. Visualizing of spots was effected with UV-light and/or vanillin in EtOH/H2SO4. Flash 
chromatography was performed with Merck silica gel 60, 40-63 μm. HRMS was recorded on 
a Micromass Q-Tof Micro (3000 V) apparatus or a Q Exactive Quadrupole-Orbitrap Mass 
Spectrometer. LC-MS was recorded a Q Exactive Quadrupole-Orbitrap Mass Spectrometer 
coupled to a UPLC Ultimate 3000 (Kinetex EVO C18; 1.7µm; 100mm x 2.1mm column with 
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a flow rate of 0.45 mL min-1 with the following gradient: a linear gradient of solvent B from 
5% to 95% over 7.5 min (solvent A = H2O + 0.1% formic acid, solvent B = acetonitrile + 
0.1% formic acid) equipped with a DAD UV/VIS 3000 RS detector. HPLC analysis was 
performed on a Dionex instrument equipped with an Uptisphere® (ODB, 5 μm, 120 Å, 
4.6×250 mm) and a Dionex UVD 340 detector. X-ray data were collected at 100K with an 
Oxford Diffraction Xcalibur 2 diffractometer equipped with a copper microsource (λ = 1.5418 
Å). 
 
General Procedure A: Acetylation of the N-terminal amine of peptoids using Ac2O. 
To a solution of peptoid (1 equiv.) and Et3N (4 equiv.) in EtOAc (0.2 M) was added Ac2O (8 
equiv.). After stirring overnight at room temperature, the precipitate was filtered off and 
rinsed with EtOAc. The filtrate was then concentrated under reduced pressure, and purified by 
column chromatography on silica gel. 
General Procedure B: Saponification using LiOH.H2O. 
To a solution of peptoid (1 equiv.) in a mixture THF/MeOH/H2O (4/1/1, v/v) was added 
LiOH.H2O (3 equiv.). After stirring for 3 h at room temperature, the mixture was acidified 
with HCl 1N and extracted with EtOAc. The organic layer was dried over Na2SO4 and then 
concentrated in vacuo. The crude peptoid acid was used in the peptide-type coupling reaction 
without further purification. 
General Procedure C: Coupling reaction with the Mukaiyama reagent (2-
chloromethylpyridinium iodide). 
To a solution of the peptoid acid (1.0 equiv.) in CH2Cl2 (0.03 M), was added the Mukaiyama 
reagent (1.5 equiv.). The mixture was stirred at room temperature for 1 h then a mixture of 
peptoid amine (1.0 equiv.) and Et3N (3.0 equiv.) in solution in CH2Cl2 was added dropwise. 
After stirring for 2 h at room temperature, the resulting mixture was diluted with EtOAc and 
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washed with water. The resulting organic layer was dried over Na2SO4 and concentrated 
under reduced pressure. 
General Procedure D : Coupling reaction with the Mukaiyama reagent and DMAP. 
To a solution of the peptoid acid (1.0 equiv.) in CH2Cl2 (0.03 M), was added the peptoid 
amine (1.0 equiv.), Et3N (6.0 equiv.), DMAP (1.0 equiv.) and the Mukaiyama reagent 
(1.5 equiv.). After stirring for 3 h at room temperature, the resulting mixture was diluted with 
EtOAc and washed with water. The organic layer was dried over Na2SO4 and concentrated 
under reduced pressure. 
Ethyl 2-[3-(N-tert-butylacetamido)-N-phenylpropanamido]acetate (4). 
To a solution of aniline (3.21 mL, 23.95 mmol,) in CHCl3 (10 mL), was added ethyl 
bromoacetate (1.33 mL, 11.98 mmol). The reaction was stirred at room temperature for 2 h 
then concentrated under reduced pressure. The crude was dissolved in EtOH (10 mL), cooled 
to 0 °C and cold water (1 – 2 mL) was added to the mixture resulting in the appearance of a 
precipitate. The solid was filtered off, washed with cold water and dried to provide ethyl 2-
(phenylamino)acetate 132 (1.16 g, 54 %) as a dark solid. 1H NMR (400 MHz, CDCl3) δ 1.30 
(t, J = 7.1 Hz, 3H, H8), 3.91 (s, 2H, H2), 4.25 (q, J = 7.1 Hz, 2H, H7), 6.60 – 6.67 (m, 2H, H5), 
6.77 (td, J = 1.1, 7.3 Hz, 1H, H6), 7.15 – 7.24 (m, 2H, H4). To a solution of amine 1 (872.3 
mg, 4.87 mmol) in dry THF (10 mL) at 0 °C, was added Et3N (2.04 mL, 14.60 mmol) and 
acryloyl chloride (475 µL, 5.84 mmol). The reaction was stirred at 0 °C for 3 h and the solid 
was filtered off. The filtrate was concentrated under reduced pressure and purified by flash 
chromatography on silica gel, eluting with cyclohexane/EtOAc (7/3, v/v) to provide ethyl 2-
(N-phenylprop-2-enamido)acetate 2 (876 mg, 77 %) as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 1.27 (t, J = 7.1 Hz, 3H, H8), 4.20 (q, J = 7.2 Hz, 2H, H7), 4.45 (s, 2H, H2), 5.57 (dd, 
J = 2.0, 10.3 Hz, H11trans), 6.09 (dd, J = 10.3, 16.8 Hz, 1H, H10), 6.41 (dd, J = 1.9, 16.8 Hz, 
1H, H11cis), 7.30 – 7.45 (m, 5H, H4-6). 13C NMR (101 MHz, CDCl3) δ 14.3 (C8), 51.7 (C2), 
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61.4 (C7), 127.9 (C10), 128.2 (Car), 128.6 (C11), 129.8 (Car), 142.3 (C3), 166.0 (C9), 169.1 (C1). 
To a solution of acrylamide 2 (876 mg, 3.76 mmol) in EtOH (10 mL), was added tert-
butylamine (1.58 mL, 15.02 mmol). The reaction was stirred at 55 °C for 16 h, then 
concentrated under reduced pressure. The crude ethyl 2-[3-(tert-butylamino)-N-
phenylpropanamido]acetate 3 (1.067 g, 93 %) obtained as a yellow oil was used in the next 
step without further purification. 1H NMR (400 MHz, CDCl3) δ 1.07 (s, 9H, H13), 1.26 (t, J = 
7.2 Hz, 3H, H8), 2.33 (t, J = 6.7 Hz, 2H, H10), 2.78 (t, J = 6.7 Hz, 2H, H11), 4.19 (q, J = 7.2 
Hz, 2H, H7), 4.34 (s, 2H, H2), 7.31 – 7.43 (m, 5H, H4-6). 13C NMR (101 MHz, CDCl3) δ 14.3 
(C8), 29.0 (C13), 35.4 (C10), 38.4 (C11), 50.6 (C12), 51.4 (C2), 61.4 (C7), 128.3 (C4), 128.5 (C6), 
129.9 (C5), 142.7 (C3), 169.3 (C1), 172.8 (C9). Compound 3 (644.5 mg, 2.10 mmol) was 
submitted to general procedure A. The crude was purified by flash chromatography, eluting 
with cyclohexane/EtOAc (4/6, v/v) to afford the expected compound 4 (546.0 mg, 75 %) as a 
pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 1.21 – 1.32 (m, 12H, H8 and H13), 1.94 (s, 3H, 
H15), 2.32 – 2.41 (m, 2H, H10), 3.52 – 3.61 (m, 2H, H11), 4.21 (q, J = 7.1 Hz, 2H, H7), 4.34 (s, 
2H, H2), 7.31 – 7.48 (m, 5H, H4-6). 13C NMR (101 MHz, CDCl3) δ 14.3 (C8), 24.9 (C15), 29.0 
(C13), 36.0 (C10), 42.8 (C11), 51.3 (C2), 57.1 (C12), 61.5 (C7), 128.0 (C4), 128.9 (C6), 130.2 
(C5), 142.5 (C3), 169.1 (C1), 170.8 (C9), 171.4 (C14). HRMS (ESI): calc. for C19H29O4N2 
[M+H]+: 349.2122, found 349.2116. 
Ethyl 2-(3-{N-tert-butyl-2-[3-(N-tert-butylacetamido)-N-phenylpropanamido]acetamido} 
-N-phenylpropanamido)acetate (6). 
Compound 4 (220.0 mg, 0.63 mmol) was submitted to general procedure B  to afford the 
crude 2-[3-(N-tert-butylacetamido)-N-phenylpropanamido]acetic acid 5 (97.0 mg, 48 %) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 1.28 (s, 9H, H11), 1.97 (s, 3H, H13), 2.33 – 2.44 
(m, 2H, H8), 3.55 – 3.61 (m, 2H, H9), 4.38 (s, 2H, H2), 7.31 – 7.50 (m, 5H, H4-6). General 
procedure C was applied using carboxylic acid 5 (97.0 mg, 0.30 mmol) and amine 3 (91.9 mg, 
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0.30 mmol). The crude was purified by flash chromatography, eluting with 
cyclohexane/EtOAc (1/9, v/v) to provide the expected tetramer 6 (97.8 mg, 53 %) as a pale 
yellow gum. 1H NMR (400 MHz, CDCl3) δ 1.25 (d, J = 7.7 Hz, 21H, H21 and H10 and H25), 
1.90 (s, 3H, H23), 2.30 – 2.38 (m, 2H, H18), 2.41 – 2.48 (m, 2H, H7), 3.44 – 3.56 (m, 4H, H8 
and H19), 4.18 (q, J = 7.2 Hz, 2H, H24), 4.22 (s, 2H, H12), 4.31 (s, 2H, H2), 7.28 – 7.48 (m, 
10H, H14-16 and H4-6). 13C NMR (101 MHz, CDCl3) δ 14.3 (C25), 24.9 (C23), 28.8 (C10), 28.9 
(C20), 35.9 (C7), 36.1 (C18), 41.0 (C8), 43.0 (C19), 51.4 (C2), 53.1 (C12), 57.0 (C9), 57.7 (C20), 
61.5 (C24), 128.0 (C4), 128.2 (C14), 128.4 (C6), 128.8 (C16), 129.8 (C5), 130.1 (C15), 142.4 
(C3), 143.2 (C13), 167.5 (C11), 169.0 (C1), 170.3 (C17), 170.7 (C6), 171.5 (C22). HRMS (ESI): 
calc. for C34H49O6N4 [M+H]+: 609.3647, found 609.3650. 
Ethyl 3-[2-(N-tert-butylacetamido)-N-phenylacetamido]propanoate (10). 
To a solution of aniline (490 µL, 5.37 mmol) in water (1 mL), was added ethyl acrylate (16.11 
mmol, 1.78 mL), and trifluoroethanol (10.74 mmol, 782 µL). After one night at reflux, the 
reaction was cooled to room temperature and extracted with EtOAc. The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. The crude was purified by flash 
chromatography, eluting with cyclohexane/EtOAc (8/2, v/v) to yield ethyl 3-
(phenylamino)propanoate 733 (635.5 mg, 61 %) as a pale yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 1.26 (t, J = 7.2 Hz, 3H, H9), 2.61 (t, J = 6.4 Hz, 2H, H2), 3.46 (t, J = 6.4 Hz, 2H, 
H3), 4.09 (s, 1H, NH), 4.16 (q, J = 7.1 Hz, 2H, H8), 6.61 – 6.66 (m, 2H, H5), 6.72 (tt, J = 1.1, 
7.3 Hz, 1H, H7), 7.15 – 7.22 (m, 2H, H6). To a solution of 7 (661 mg, 3.42 mmol) in dry THF 
(5 mL) at – 20 °C, was added Et3N (4.11 mmol, 573 µL) and bromoacetyl bromide 
(4.11 mmol, 358 µL). The reaction was stirred at – 20 °C for 2 – 3 h. After completion, 
monitored by TLC, the reaction was filtered and the filtrate was concentrated under reduced 
pressure. The crude was purified by flash chromatography, eluting with cyclohexane/EtOAc 
(6/4, v/v) to provide ethyl 3-(2-bromo-N-phenylacetamido)propanoate 8 (633.0 mg, 59 %) as 
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a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 1.20 (t, J = 7.1 Hz, 3H, H9), 2.60 (t, J = 7.3 
Hz, 2H, H2), 3.62 (s, 2H, H11), 3.97 – 4.10 (m, 4H, H3 and H8), 7.26 – 7.30 (m, 2H, H6), 7.36 
– 7.51 (m, 3H, H5 and H7). 13C NMR (101 MHz, CDCl3) δ 14.2 (C6), 27.2 (C11), 32.7 (C2), 
46.2 (C3), 60.8 (C8), 128.2 (C6), 129.0 (C7), 130.2 (C5), 141.3 (C4), 166.6 (C10), 171.3 (C1). To 
a solution of 8 (633 mg, 2.01 mmol) in dry THF (5 mL) at room temperature, was added Et3N 
(4.03 mmol, 562 µL) and tert-butylamine (8.06 mmol, 847 µL). The reaction was stirred 
overnight. After completion, monitored by TLC, the reaction was filtered and the liquid was 
concentrated under reduced pressure. The crude ethyl 3-[2-(tert-butylamino)-N-
phenylacetamido]propanoate 9 (582 mg, 94 %) obtained as a pale yellow oil was engaged in 
the next step without purification. 1H NMR (400 MHz, CDCl3) δ 0.99 (s, 9H, H12), 1.19 (t, J = 
7.1 Hz, 3H, H9), 2.58 (t, J = 7.4 Hz, 2H, H2), 3.05 (s, 2H, H11), 4.03 (m, 4H, H3 and H8), 7.14 
– 7.21 (m, 2H, H6), 7.34 – 7.51 (m, 3H, H5 and H7). 13C NMR (101 MHz, CDCl3) δ 14.2 (C9), 
28.5 (C12), 32.9 (C2), 44.7 (C11), 45.7 (C2), 50.9 (C13), 60.7 (C8), 128.2 (C6), 128.7 (C7), 130.1 
(C5), 140.9 (C4), 171.1 (C10), 171.4 (C1). Compound 9 (639 mg, 2.09 mmol) was submitted to 
general procedure A. The crude was purified by flash chromatography on silica gel, eluting 
with EtOAc/cyclohexane (6/4, v/v) to afford compound 10 (565.3 mg, 78 %) as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ 1.20 (t, J = 7.1 Hz, 3H, H9), 1.36 (s, 9H, H12), 1.97 (s, 3H, 
H13), 2.57 (t, J = 7.1 Hz, 2H, H2), 3.69 (s, 2H, H11), 3.93 – 4.12 (m, 4H, H8 and H3), 7.21 – 
7.25 (m, 2H, H6), 7.37 – 7.53 (m, 3H, H5 and H7). 13C NMR (101 MHz, CDCl3) δ 14.2 (C9), 
25.1 (C13), 28.6 (C12), 33.1 (C2), 45.9 (C3), 49.2 (C11), 57.3 (C14), 60.8 (C8), 128.2 (C6), 129.1 
(C7), 130.5 (C5), 140.9 (C4), 169.1 (C10), 171.4 (C1 or C15), 171.8 (C1 or C15). HRMS (ESI): 
calc. for C19H29O4N2 [M+H]+: 349.2122, found 349.2115. 
Ethyl 3-(2-{N-tert-butyl-3-[2-(N-tert-butylacetamido)-N-phenylacetamido] 
propanamido}-N-phenylacetamido)propanoate (12). 
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Compound 10 (565.3 mg, 1.62 mmol) was submitted to general procedure B to afford the 
crude 3-[2-(N-tert-butylacetamido)-N-phenylacetamido]propanoic acid 11 (387.0 mg, 75 %) 
as a white solid. 1H NMR (400 MHz, CDCl3) δ 1.35 (s, 9H, H11), 1.99 (s, 3H, H13), 2.58 (t, J 
= 6.8 Hz, 2H, H2), 3.71 (s, 2H, H9), 4.03 (s, 2H, H3), 7.27 (s, 2H, H6), 7.47 (m, 3H, H5 and 
H7). The general procedure C was applied using the carboxylic acid 11 (50 mg, 0.16 mmol) 
and the amine 9 (50 mg, 0.16 mmol). The crude was purified by flash chromatography on 
silica gel, eluting with EtOAc to afford the tetramer 12 (43.2 mg, 46 %) as a yellow gum. 1H 
NMR (400 MHz, CDCl3) δ 1.20 (t, J = 7.1 Hz, 3H, H14), 1.31 (s, 9H, H20), 1.38 (s, 9H, H26), 
2.01 (s, 3H, H12), 2.50 – 2.60 (m, 4H, H2 and H7), 3.73 (s, 2H, H10), 3.88 (s, 4H, H5 and H8), 
4.00 (t, J = 7.3 Hz, 2H, H3), 4.06 (q, J = 7.1 Hz, 2H, H13), 7.23 (d, J = 7.6 Hz, 2H, H22), 7.33 
(d, J = 7.5 Hz, 2H, H16), 7.38 – 7.52 (m, 6H, Har). 13C NMR (101 MHz, CDCl3) δ 14.3 (C14), 
25.2 (C12), 28.5 (C20), 28.7 (C26), 33.0 (C2), 35.1 (C7), 45.9 (C3), 47.5 (C5 or C8), 48.5 (C5 or 
C8), 49.2 (C10), 57.3 (C25), 57.7 (C19), 60.8 (C13), 128.0 (C22), 128.4 (C15), 128.8 (C24), 129.1 
(C18), 130.3 (C23), 130.5 (C17), 140.7 (C15), 141.5 (C21), 169.2 (C9 or C5 or C4), 169.3 (C9 or 
C5 or C4), 171.3 (C1), 171.5 (C9 or C5 or C4), 171.9 (C11). HRMS (ESI): calc. for C34H49O6N4 
[M+H]+: 609.3647, found 609.3650. 
Ethyl 2-(N-tert-butylprop-2-enamido)acetate (14). 
To a solution of ethylbromo acetate (1.33 mL, 11.98 mmol) in dry THF (20 mL) at room 
temperature, was added Et3N (3.34 mL, 23.95 mmol) and tert-butylamine (5.03 mL, 47.90 
mmol). The reaction was stirred overnight. After completion, monitored by TLC, the reaction 
was filtered and the liquid was concentrated under reduced pressure. The crude ethyl 2-(tert-
butylamino)acetate 13 (1.17 g, 62 %, colorless oil) was used in the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 1.04 (s, 9H, H4), 1.21 (t, J = 7.1 Hz, 3H, H6), 3.33 
(s, 2H, H2), 4.12 (q, J = 7.2 Hz, 2H, H5). To a solution of amine 13 (500.0 mg, 3.14 mmol) in 
dry THF (20 mL) at 0 °C, was added Et3N (1.31 mL, 9.42 mmol) and acryloyl chloride 
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(306 µL, 3.78 mmol). The reaction was stirred at 0° C for 2 h and the solid was filtered off. 
The filtrate was concentrated under reduced pressure and purified by flash chromatography on 
silica gel, eluting with cyclohexane/EtOAc (7/3, v/v) to provide the expected compound 14 
(524.4 mg, 78.3 %) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 1.29 (t, J = 7.1 Hz, 3H, H9), 1.45 
(s, 9H, H4), 4.11 (s, 3H, H2), 4.22 (q, J = 7.1 Hz, 2H, H8), 5.58 (dd, J = 1.9, 10.5 Hz, 1H, H7trans), 6.18 
(dd, J = 2.0, 16.8 Hz, 1H, H6), 6.38 (dd, J = 10.4, 16.8 Hz, 1H, H7cis) 
Ethyl 2-[N-tert-butyl-3-(N-phenylacetamido)propanamido]acetate (17). 
Compound 7 (434 mg, 2.24 mmol) was submitted to general procedure A. The crude was 
purified by flash chromatography, eluting with EtOAc/cyclohexane (3/7, v/v) to provide ethyl 
3-(N-phenylacetamido)propanoate 15 (482 mg, 91 %) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 1.19 (t, J = 7.1 Hz, 3H, H11), 1.82 (s, 3H, H9), 2.57 (t, J = 7.3 Hz, 2H, H2), 3.97 – 
4.08 (m, 4H, H3 and H10), 7.17 (d, J = 7.5 Hz, 2H, H6), 7.34 (m, 1H, H7), 7.42 (t, J = 7.5 Hz, 
2H, H5). 13C NMR (101 MHz, CDCl3) δ 14.2 (C11), 22.8 (C9), 33.1 (C2), 45.2 (C3), 60.7 (C10), 
128.3 (Car), 129.9 (Car), 142.9 (Car), 170.5 (C8), 171.6 (C1). Compound 15 (482.0 mg, 2.05 
mmol) was submitted to general procedure B to afford the crude 3-(N-
phenylacetamido)propanoic acid 16 (340.0 mg, 80 %) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 1.84 (s, 3H, H9), 2.62 (t, J = 7.2 Hz, 2H, H2), 4.00 (t, J = 7.2 Hz, 2H, H3), 7.19 (dd, 
J = 1.7, 7.3 Hz, 2H, Har), 7.32 – 7.47 (m, 3H, Har). 13C NMR (101 MHz, CDCl3) δ 22.7 (C9), 
32.8 (C2), 45.4 (C3), 128.1 (Car), 128.5 (Car), 130.1 (Car), 142.5 (C4), 171.5 (C8), 175.6 (C2). 
General procedure C was applied using carboxylic acid 16 (100.0 mg, 0.48 mmol) and 
monomer amine 13 (76.4 mg, 0.48 mmol). The crude was purified by flash chromatography, 
eluting with cyclohexane/EtOAc (3/7, v/v) to provide dimer 17 (146 mg, 87 %) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 1.27 (t, J = 7.2 Hz, 3H, H15), 1.37 (s, 9H, H4), 1.82 (s, 
3H, H13), 2.56 (bs, 2H, H6), 3.95 (t, J = 7.6 Hz, 2H, H7), 4.10 (s, 2H, H2), 4.20 (q, J = 7.2 Hz, 
2H, H14), 7.09 – 7.18 (m, 2H, H9), 7.29 – 7.43 (m, 3H, H10 and H11). 13C NMR (101 MHz, 
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CDCl3) δ 14.3 (C15), 22.9 (C13), 28.7 (C4), 34.2 (C6), 46.6 (C7), 47.4 (C2), 57.8 (C3), 61.6 
(C14),128.0 (C10 and C11), 129.8 (C9), 143.4 (C8), 170.7 (C12), 170.8 (C1), 171.7 (C5). 
Ethyl 2-(N-tert-butyl-3-{2-[N-tert-butyl-3-(N-phenylacetamido)propanamido]-N-
phenylacetamido}propanamido)acetate (19).  
Compound 17 (146.0 mg, 0.42 mmol) was submitted to general procedure B to afford the 
crude 2-[N-tert-butyl-3-(N-phenylacetamido)propanamido]acetic acid (103.0 mg, 77 %) as a 
withe solid. 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H, H4), 1.87 (s, 3H, H13), 2.66 (t, J = 7.9 
Hz, 2H, H6), 3.96 (t, J = 7.6 Hz, 2H, H7), 4.16 (s, 2H, H2), 7.20 (d, J = 7.6 Hz, 2H, Har), 7.39 
(m, 3H, Har). The general procedure D was applied using the crude 2-[N-tert-butyl-3-(N-
phenylacetamido)propanamido]acetic acid (100.0 mg, 0.31 mmol,) and the monomer amine 7 
(59.9 mg, 0.31 mmol). The crude was purified by flash chromatography, eluting with 
cyclohexane/EtOAc (3/7, v/v) to provide ethyl 3-{2-[N-tert-butyl-3-(N-
phenylacetamido)propanamido]-N-phenylacetamido} propanoate 18 (80 mg, 52 %) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.18 – 1.23 (m, 3H, H22), 1.31 (s, 9H, H11), 1.84 
(s, 3H, H20), 2.52 (m, 2H, H13), 2.59 (t, J = 7.4 Hz, 2H, H2), 3.79 (s, 2H, H9), 3.91 (m, 2H, 
H14), 3.97 – 4.12 (m, 4H, H3 and H21), 7.19 (d, J = 7.7 Hz, 2H, Har), 7.28 – 7.57 (m, 8H, Har). 
13C NMR (101 MHz, CDCl3) δ 14.3 (C23), 23.0 (C20), 28.6 (C11), 33.0 (C2), 34.5 (C13), 45.9 
(C3), 48.3 (C14), 57.5 (C15), 60.8 (C21), 128.0 (Car), 128.1 (Car), 128.3 (Car), 129.0 (Car), 129.8 
(Car), 130.4 (Car), 140.9 (Car), 143.6 (Car), 169.2 (C8), 170.7 (C19), 171.4 (C1), 171.8 (C12).  
The general procedure B was applied using the ester 18 (60 mg 0.12 mmol) to afford the 
crude ethyl 3-{2-[N-tert-butyl-3-(N-phenylacetamido)propanamido]-N-
phenylacetamido}propanoic acid (44.0 mg, 77 %) as a white solid.1H NMR (400 MHz, 
CDCl3) δ 1.28 (s, 9H, H11), 1.94 (s, 3H, H20), 2.47 (m, 4H, H2 and H13), 3.68 (s, 2H, H9), 4.03 
(bs, 4H, H3 and H14), 7.28 – 7.66 (m, 10H, Har). The general procedure D was applied using 
ethyl 3-{2-[N-tert-butyl-3-(N-phenylacetamido)propanamido]-N-phenylacetamido}propanoic 
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acid (100.0 mg, 0.31 mmol,) and the monomer amine 13 (49.3 mg, 0.31 mmol). The crude 
was purified by flash chromatography, eluting with cyclohexane/EtOAc (3/7, v/v) to afford 
the expected tetramer 19 (80 mg, 52 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.26 
(t, J = 7.1 Hz, 3H, H26), 1.31 (s, 9H, H15), 1.38 (s, 9H, H4), 1.83 (s, 3H, H24), 2.52 (bs, 2H, 
H17), 2.60 (bs, 2H, H6), 3.79 (s, 2H, H13), 3.91 (t, J = 7.0 Hz, 2H, H18), 3.99 (t, J = 7.0 Hz, 2H, 
H7), 4.13 (s, 2H, H2), 4.19 (q, J = 7.1 Hz, 2H, H25), 7.15 – 7.22 (m, 2H, Har), 7.27 – 7.50 (m, 
7H, Har). 13C NMR (101 MHz, CDCl3) δ 14.3 (C26), 23.0 (C24), 28.6 (C15), 28.7 (C4), 34.2 
(C6), 34.6 (C17), 46.9 (C18), 47.0 (C7), 47.4 (C2), 48.4 (C13), 57.6 (C14), 57.8 (C3), 61.6 (C25), 
127.9 (CAr), 128.1 (CAr), 128.2 (CAr), 128.8 (CAr), 129.8 (CAr), 130.3 (CAr), 141.5 (CAr), 143.6 
(CAr), 169.2 (C12), 170.6 (C24), 170.9 (C1), 171.5 (C5 or C16), 171.6 (C5 or C16). HRMS (ESI): 
calc. for C34H49O6N4 [M+H]+: 609.3647, found 609.3652. 
Ethyl 3-[N-tert-butyl-2-(phenylamino)acetamido]propanoate (22). 
To a solution of ethylacrylate (10.00 g, 99.88 mmol) in EtOH (0.2 M) at room temperature, 
was added tBuNH2 (29.22 g, 42 mL, 4 equiv.). After stirring for 16 h at 60 °C, the mixture 
was cooled down then concentrated and dried in vacuo, yielding the crude ethyl 3-(tert-
butylamino)propanoate 20. The crude was purified on flash chromatography, eluting with 
cyclohexane/EtOAc (8/2, v/v) to provide the expected compound 20 (14.47 g, 83.51 mmol, 84 
%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.11 (s, 9H, H9), 1.26 (t, J = 6.8 Hz, 3H, 
H7), 2.49 (t, J = 6.5 Hz, 2H, H2), 2.82 (t, J = 6.6 Hz, 2H, H3), 4.14 (q, J = 7.2 Hz, 2H, H6). 13C 
NMR (101 MHz, CDCl3) δ 14.4 (C7), 29.1 (C5), 35.8 (C2), 38.2 (C3), 50.6 (C4), 60.5 (C6), 
173.1 (C1). To a solution of 20 (1.02 g, 5.88 mmol,) in dry THF (5 mL) at - 20 °C, was added 
Et3N (985 µL, 7.07 mmol) and bromoacetyl bromide (615 µL, 7.07 mmol). The reaction was 
stirred at - 20 °C for 2 – 3 h. After completion, monitored by TLC, the reaction was filtered 
and the liquid was concentrated under reduced pressure. The crude was purified on flash 
chromatography, eluting with cyclohexane/EtOAc (8/2, v/v) to provide ethyl 3-(2-bromo-N-
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tert-butylacetamido)propanoate 21 (1.33 g, 77 %) as a pale yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 1.27 (t, J = 7.3 Hz, 3H, H7), 1.45 (s, 9H, H5), 2.60 – 2.67 (m, 2H, H2), 3.64 – 3.76 
(m, 2H, H3), 3.91 (s, 2H, H9), 4.16 (q, J = 7.2 Hz, 2H, H6). 13C NMR (101 MHz, CDCl3) δ 
14.3 (C7), 28.7 (C5), 29.9 (C9), 36.9 (C2), 41.9 (C3), 58.1 (C4), 61.2 (C6), 167.5 (C8), 170.8 
(C1). To a solution of 21 (665.0 mg, 2.26 mmol) in dry THF (5 mL) was added Et3N (4.52 
mmol, 631 µL) and aniline (9.04 mmol, 826 µL). The reaction was stirred at room 
temperature for 3 days. After completion, monitored by TLC, the reaction was filtered and the 
liquid was concentrated under reduced pressure. The crude was purified on flash 
chromatography, eluting with cyclohexane/EtOAc (7/3, v/v) to provide the expected 
compound 22 (541 mg, 78 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.29 (t, J = 7.1 
Hz, 3H, H13), 1.49 (s, 9H, H5), 2.61 (dd, J = 6.8, 9.3 Hz, 2H, H2), 3.65 (dd, J = 6.7, 9.5 Hz, 
2H, H3), 3.90 (s, 2H, H7), 4.18 (q, J = 7.2 Hz, 2H, H12), 6.67 (d, J = 7.9 Hz, 2H, H10), 6.74 (t, J 
= 7.4 Hz, 1H, H11), 7.20 (t, J = 7.4 Hz, 2H, H9). 13C NMR (101 MHz, CDCl3) δ 14.3 (C13), 
28.9 (C5), 36.5 (C2), 39.8 (C3), 47.5 (C7), 58.1 (C4), 61.2 (C12), 113.6 (C10), 118.1 (C11), 129.4 
(C9), 147.2 (C8), 169.2 (C6), 170.8 (C1). HRMS (ESI): calc. for C17H27N2O3 [M+H]+: 
307.2016, found 307.2019. 
Ethyl 3-(N-tert-butyl-2-{3-[N-tert-butyl-2-(N-phenylacetamido)acetamido]-N-
phenylpropanamido}acetamido)propanoate (27). 
To a solution of 22 (541.0 mg, 1.77 mmol,) in dry THF (5 mL) at 0 °C, was added Et3N (738 
µL, 5.30 mmol) and acryloyl chloride (172 µL, 2.12 mmol). The reaction was stirred at 0 °C 
for 3 h. After completion, monitored by TLC, the reaction was filtered and the liquid was 
concentrated under reduced pressure. The crude was purified by flash chromatography, 
eluting with cyclohexane/EtOAc (1/1, v/v) to provide ethyl 3-[N-tert-butyl-2-(N-phenylprop-
2-enamido)acetamido]propanoate 23 (617 mg, 97 %) as a pale yellows oil. 1H NMR (400 
MHz, CDCl3) δ 1.25 (t, J = 7.1 Hz, 3H, H16), 1.44 (s, 9H, H5), 2.67 – 2.76 (m, 2H, H2), 3.56 – 
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3.67 (m, 2H, H3), 4.12 (q, J = 7.2 Hz, 2H, H15), 4.50 (s, 2H, H15), 5.54 (d, J = 10.4 Hz, 1H, 
H14), 6.13 (dd, J = 10.6, 16.2 Hz, 1H, H13), 6.37 (d, J = 16.8 Hz, 1H, H14), 7.29 – 7.44 (m, 5H, 
Har). 13C NMR (101 MHz, CDCl3) δ 14.3 (C16), 29.0 (C5), 36.3 (C2), 40.3 (C3), 53.7 (C7), 
57.9 (C4), 61.0 (C15), 127.8 (C14), 128.0 (C13), 128.3 (Car), 128.4 (Car), 129.5 (Car), 143.1 (C8), 
166.0 (C12), 167.8 (C6), 171.1 (C1). To a solution of 23 (617.0 mg, 1.71 mmol) in EtOH (10 
mL) at room temperature, was added tBuNH2 (720 µL, 6.85 mmol). The reaction was stirred 
at 65°C for 16 h. After completion, monitored by TLC, the reaction was concentrated under 
reduced pressure. The crude ethyl 3-{N-tert-butyl-2-[3-(tert-butylamino)-N-
phenylpropanamido]acetamido}propanoate 24 (659 mg, 89 %) obtained as a pale yellows oil 
was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 1.09 (s, 
9H, H16), 1.24 (t, J = 7.2 Hz, 3H, H18), 1.43 (s, 9H, H5), 2.38 (t, J = 6.9 Hz, 2H, H13), 2.65 (dd, 
J = 6.6, 9.7 Hz, 2H, H2), 2.81 (t, J = 6.7 Hz, 2H, H14), 3.58 (dd, J = 6.6, 9.7 Hz, 2H, H3), 4.11 
(q, J = 7.3 Hz, 2H, H17), 4.40 (s, 2H, H7), 7.27 – 7.50 (m, 5H, Har). 13C NMR (101 MHz, 
CDCl3) δ 14.3 (C18), 28.8 (C15), 29.0 (C5), 35.1 (C13), 36.3 (C2), 38.6 (C14), 40.2 (C3), 53.4 
(14), 51.0 (C15), 57.9 (C4), 61.0 (C17), 128.1 (Car), 128.4 (Car), 129.7 (Car), 143.3 (C8), 167.9 
(C6), 171.1 (C1), 172.5 (C12). To a solution of 24 (659 mg, 1.52 mmol) in dry THF (5 mL) at – 
20 °C, was added Et3N (254 µL, 1.82 mmol) and bromoacetyl bromide (159 µL, 1.82 mmol). 
The reaction was stirred at – 20 °C for 2 – 3 h. After completion, monitored by TLC, the 
reaction was filtered and the liquid was concentrated under reduced pressure. The crude was 
purified by flash chromatography, eluting with cyclohexane/EtOAc (1/1, v/v) to provide ethyl 
3-{2-[3-(2-bromo-N-tert-butylacetamido)-N-phenylpropanamido]-N-tert-
butylacetamido}propanoate 25 (283 mg, 34 %) as a pale yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 1.25 (t, J = 7.1 Hz, 3H, H20), 1.30 (s, 9H, H16 or H5), 1.44 (s, 9H, H16 or H5), 2.37 – 
2.50 (m, 2H, H13), 2.56 – 2.72 (m, 2H, H2), 3.54 – 3.65 (m, 4H, H3 and H14), 3.67 (s, 2H, H18), 
4.12 (q, J = 7.2 Hz, 2H, H19), 4.41 (s, 2H, H7), 7.34 – 7.46 (m, Har). 13C NMR (101 MHz, 
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CDCl3) δ 14.31 (C19), 28.59 (C16 or C5), 28.99 (C16 or C5), 30.20 (C16), 36.33 (C2), 36.75 
(C13), 40.27 (C3), 42.65 (C14), 53.44 (C7), 57.97 (C15 or C4), 58.03 (C15 or C4), 61.03 (C19), 
128.27 (Car), 128.69 (Car), 130.06 (Car), 143.17 (C8), 167.43 (C6), 167.46 (C17), 170.31 (C12), 
171.06 (C1). To a solution of 25 (283.0 mg, 0.51 mmol) in dry THF (5 mL) was added Et3N 
(142 µL, 1.02 mmol) and aniline (186 µL, 2.04 mmol). The reaction was stirred at room 
temperature for 48 hours. After completion, monitored by TLC, the reaction was filtered and 
the liquid was concentrated under reduced pressure. The crude was purified by flash 
chromatography, eluating with cyclohexane/EtOAc (6/4, v/v) to provide ethyl 3-(N-tert-butyl-
2-{3-[N-tert-butyl-2-(phenylamino)acetamido]-N-phenylpropanamido}acetamido)propanoate 
26 (183 mg, 63 %) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 1.26 (t, J = 7.1 Hz, 3H, 
H24), 1.33 (s, 9H, H5), 1.45 (s, 9H, H16), 2.39 – 2.48 (m, 2H, H13), 2.59 – 2.71 (m, 2H, H2), 
3.59 (t, J = 7.0 Hz, 4H, H3 and H14), 3.78 (s, 2H, H18), 4.13 (q, J = 7.1 Hz, 2H, H23), 4.42 (s, 
2H, H7), 6.65 – 6.84 (m, 3H, Har), 7.17 – 7.24 (m, 2H, Har), 7.28 – 7.49 (m, 5H, Har). 13C 
NMR (101 MHz, CDCl3) δ 14.3 (C24), 28.8 (C5), 29.0 (C16), 36.0 (C13), 36.4 (C2) 40.3 (C3), 
40.7 (C14), 47.7 (C18), 53.5 (C7), 58.0 (C16), 58.1 (C5), 61.4 (C23), 114.2 (CAr), 128.1 (CAr), 
128.7 (CAr), 129.4 (CAr), 130.1 (CAr), 143.1 (CAr), 167.5 (C6), 168.9 (C17), 170.4 (C12), 171.0 
(C1). The general procedure A was applied using compound 26 (183.0 mg, 0.32 mmol) as 
starting material. The crude was purified by flash chromatography, eluting with 
cyclohexane/EtOAc (3/7, v/v) to afford the expected compound 27 (167 mg, 85 %) as a pink 
oil. 1H NMR (400 MHz, CDCl3) δ 1.20 – 1.29 (m, 12H, H26 and H16), 1.43 (s, 9H, H5), 1.89 
(s, 3H, H24), 2.44 – 2.52 (m, 2H, H13), 2.60 – 2.69 (m, 2H, H2), 3.48 – 3.54 (m, 2H, H14), 3.54 
– 3.60 (m, 2H, H3), 4.12 (q, J = 7.1 Hz, 2H, H25), 4.20 (s, 2H, H18), 4.38 (s, 2H, H7), 7.27 – 
7.45 (m, Har). 13C NMR (101 MHz, CDCl3) δ 14.3 (C26), 22.4 (C24), 28.8 (C16), 29.0 (C5), 
36.1 (C13), 36.3 (C2), 40.3 (C3), 41.2 (C14), 53.1 (C18), 53.4 (C7), 57.7 (C15), 57.9 (C4), 61.0 
(C25), 127.8 (Car), 128.2 (Car), 128.3 (Car), 128.4 (Car), 129.5 (Car), 129.9 (Car), 143.2 (C8), 
 41
144.3 (C19), 167.6 (C6), 168.0 (C17), 170.6 (C12 and C23), 171.0 (C1). HRMS (ESI): calc. for 
C34H49O6N4 [M+H]+: 609.3647, found 609.3742. 
Computational Details. 
Preparation of structures for quantum calculations. The structures for quantum calculations 
were prepared with the help of gauss view package.34 The ω dihedral angle was considered to 
be in cis conformation for NtBu residues and trans for NPh residues. Dihedrals angles were 
initially set from those determined by X–ray crystallography of oligopeptoids that display an 
analogy of backbone. All oligomers were capped with acyl and NMe2 group at N- and C- 
termini, respectively, in order to mimic a full polypeptide backbone and avoid spurious 
capping effects. This capping can from the ester termination of some oligopeptoids 
synthetized. 
Quantum calculation. All quantum calculations were performed with Gaussian09 suite of 
programs.35 All full optimizations, as well as frequency calculations, were performed at 
Density Functional Theory (DFT) level M06-2X hybrid meta-GGA functional.36 Carbon and 
hydrogen atoms were represented with the polarized all electron 6-311G(d,p) basis sets while 
nitrogen and oxygen atoms were represented with the augmented and polarized all electron 6-
311++G(d,p) basis sets.37 No symmetry nor geometry constrain was included during the 
optimization. Implicit solvent environment was considered using the SMD solvent model 
parameterized for dichloromethane.38 The energetics related to a φ dihedral angle sign change 
has been assessed by means of a relaxed energy scan was performed for this angle. The scan 
was performed from 90o to –90o with increment of 5o at restricted Hartee Fock level using 
Ahlrichs-VDZ split valence basis set.39 A single point energy calculation was then performed 
on the constrained optimized structure at DFT level using above mentioned functional and 
basis sets. All minima and transition states were finally fully optimized at M06-2X level using 
the polarized all electron 6-311G(d,p) basis set for all atoms. 
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Setup for Molecular Dynamics (MD) simulation. The Generalized AMBER Force Field 
(GAFF)40 parameters were used to describe the potential of NtBu peptoid monomers. The 
RESP charges were generated using RED server41 followed by the antechamber module42 of 
AMBER to make the parameter/topology (parm) file. The peptoid oligomers were capped by 
acetyl group at N-terminus and N,N-dimethyl at C-terminus. The peptoid oligomers were 
solvated in acetonitrile box with a buffer of 16 Å towards each direction.  
Molecular Dynamics simulation. All Molecular Dynamics simulations were performed using 
NAMD software package.43 Timestep of 1 femtosecond was applied for each simulation. A 
cutoff of 14Å was applied for non-bonded interactions while Particle Mesh Ewald summation 
was applied for electrostatic interactions. The system was initially minimized for 200 steps. 
This was followed by equilibration at NVT ensemble. During this NVT equilibration the 
temperature was gradually raised from 5K to 315K with an increment of 10K. At each 
temperature 5000 steps (5 picoseconds) of simulation was performed. This was followed by 
200 picoseconds of NVT equilibration at 300K. Thereafter the system was subjected to 400 
picoseconds of equilibration at NPT ensemble. The temperature was kept fixed at 300K 
through Langevin dynamics with a damping coefficient of 5/ps while the pressure was 
controlled at 1 atm using Nose-Hoover Langevin piston. From the equilibrated system two 
initial production runs of each 10 nanoseconds were performed. The resultant snapshots were 
subjected to another two similar production run each. A final production run of 50 
nanoseconds was performed from the final snapshot of the initial production run. The 
trajectory was stored for every 2 picoseconds. The trajectory from this final production run 
was used for calculation of all equilibrium properties. A similar protocol was followed for 
peptoid oligomers with alternating positive and negative φ dihedral angles. 
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